Headlines about Globus Medical (NYSE:GMED) have trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Globus Medical earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 45.61629810985 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Globus Medical (NYSE GMED) opened at 29.28 on Friday. The company has a market capitalization of $2.82 billion, a PE ratio of 26.38 and a beta of 0.60. The stock’s 50 day moving average is $29.82 and its 200-day moving average is $30.72. Globus Medical has a 12 month low of $19.25 and a 12 month high of $34.03.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The company had revenue of $152.39 million for the quarter, compared to analyst estimates of $150.94 million. During the same period in the prior year, the firm posted $0.29 EPS. The company’s quarterly revenue was up 10.8% on a year-over-year basis. On average, analysts expect that Globus Medical will post $1.27 EPS for the current year.

Several research firms recently issued reports on GMED. BidaskClub raised shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 22nd. Zacks Investment Research lowered shares of Globus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Morgan Stanley reissued an “equal weight” rating on shares of Globus Medical in a research report on Tuesday, July 11th. Barclays PLC reissued an “underweight” rating and issued a $28.00 price target (down previously from $30.00) on shares of Globus Medical in a research report on Thursday, August 3rd. Finally, Oppenheimer Holdings, Inc. set a $35.00 price target on shares of Globus Medical and gave the stock a “hold” rating in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the stock. Globus Medical has an average rating of “Hold” and an average price target of $31.38.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.watchlistnews.com/globus-medical-gmed-receives-news-sentiment-score-of-0-16/1581925.html.

In related news, insider A Brett Murphy sold 15,000 shares of the stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total transaction of $449,850.00. Following the transaction, the insider now directly owns 101,217 shares of the company’s stock, valued at $3,035,497.83. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 28.21% of the stock is owned by corporate insiders.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.